Albion Venture Capital Trusts close £90M top-up offer as demand for UK innovation investments grows

Albion Venture Capital Trusts has successfully closed its £90 million top-up fundraising round as of March 2026, with the offering oversubscribed against an initial £60 million target. The completion of this raise reflects sustained institutional appetite for structured access to the UK's innovation ecosystem, particularly as investors seek tax-efficient exposure to high-growth companies across early-stage and scale-up segments.

The newly raised capital will be deployed into Albion Capital's core conviction sectors: deeptech, healthcare, and B2B software. The trusts provide investors with a diversified portfolio spanning early-stage disruptors through established scale-ups, offering both venture upside and portfolio stability. This capital deployment strategy aligns with demonstrated portfolio strength: over the past three years, 64% of portfolio companies have progressed from the growth stage to scaleup stage, indicating meaningful value creation and reduced execution risk within the underlying holdings.

The fundraise is anchored by a portfolio of established winners and emerging leaders. Quantexa, the global leader in decision intelligence solutions, remains a flagship holding. Oviva, Europe's leading digital health company focused on weight loss management, recently closed a £200 million Series D round, representing a significant validation event and potential exit inflection point. Tem, an AI-powered infrastructure platform reducing business energy costs, exemplifies deeptech exposure. Recent growth rounds for fintech innovators Gravity and TransFICC further demonstrate portfolio breadth and momentum across multiple subsectors.

Over a five-year horizon, the three Albion VCTs have cumulatively raised more than £405 million, establishing a track record of consistent capital access and institutional confidence. According to Will Fraser-Allen, Managing Partner at Albion, the oversubscription reflects "growing recognition that VCTs are one of the most effective ways to back the next generation of UK entrepreneurs, while targeting long-term, tax-efficient returns." This positioning is particularly relevant in an environment where tax efficiency and sustained growth are paramount considerations for allocators evaluating domestic venture exposure. The successful close underscores VCTs' competitive positioning as a preferred vehicle structure for institutional capital seeking UK innovation exposure alongside favorable tax treatment.